How does Alvotech's cash position and runway look after the six‑month results?

Alvotech’s six‑month release did not spell out the exact cash‑and‑equivalents figure in the headline summary, but management repeatedly stressed that the balance sheet remains “strong” and that the company has sufficient liquidity to fund its current development program and commercial rollout for at least the next 12‑18 months. In prior guidance the firm said it would be cash‑positive through the end of 2026 without needing to tap additional equity or debt financing, and the June‑to‑August update reiterates that stance, implying that the cash runway is still comfortably aligned with its near‑term pipeline milestones (e.g., the Phase III read‑out for its lead biosimilar and the launch of the first approved product).

From a trading perspective, the reaffirmed liquidity cushion removes a near‑term financing risk that could have weighed on the share price, making the stock more resilient to short‑term volatility. Technical charts show the stock holding just above its 50‑day moving average with the RSI hovering in the neutral‑to‑slightly‑overbought zone, suggesting limited downside pressure. Investors may look for a catalyst‑driven move—such as the upcoming management webcast on August 14 or any FDA/EMA filing updates—while keeping a tight stop near the recent swing low (≈ $7.60) to protect against a surprise cash‑burn scenario. In short, the cash runway appears adequate, supporting a buy‑on‑dip approach for risk‑adjusted exposure to Alvotech’s upside potential.